Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
320000 participants
INTERVENTIONAL
2022-02-07
2028-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tripartite International Research for the Elimination of Trachoma
NCT01202331
Trachoma Elimination Follow-up
NCT00221364
Trachoma Amelioration in Northern Amhara (TANA)
NCT00322972
Nepal Elimination of Trachoma Study
NCT02176057
Water Uptake for Health in Amhara Pilot
NCT02373657
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WHO-recommended
Annual mass azithromycin distribution of all residents
Azithromycin
Mass Drug Administration
Age-based core group
Annual mass azithromycin treatment of everyone plus quarterly treatment of children
Azithromycin
Mass Drug Administration
PCR infection-based core group
Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
Azithromycin
Mass Drug Administration
TI-based core group
Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
Azithromycin
Mass Drug Administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azithromycin
Mass Drug Administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Eye Institute (NEI)
NIH
Eyu-Ethiopia
UNKNOWN
Bahir Dar University
OTHER
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tom M Lietman, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Hadley Burroughs, MSPH
Role: STUDY_DIRECTOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Proctor Foundation
San Francisco, California, United States
Eyu-Ethiopia
Bahir Dar, , Ethiopia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-22201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.